1. Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in ‘Rich’ Countries?

   • Alan Haycox

   Editorial 07 June 2018 Pages: 731 - 732

2. Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?

   • Fernando Antoñanzas
   • Roberto Rodríguez-Ibeas
   • Carmelo A. Juárez-Castelló

   Leading Article 15 February 2018 Pages: 733 - 743

   

3. Discounting in Economic Evaluations

   • Arthur E. Attema
   • Werner B. F. Brouwer
   • Karl Claxton

   Review Article Open access 19 May 2018 Pages: 745 - 758

4. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Matt Stevenson
   • Abdullah Pandor
   • Ruth Wong

   Review Article 03 March 2018 Pages: 759 - 768

5. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Shijie Ren
   • Iñigo Bermejo
   • Matt Stevenson

   Review Article Open access 03 March 2018 Pages: 769 - 778

6. The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review

   • Alex Diamantopoulos
   • Emily Wright
   • Toby M. Maher

   Systematic Review Open access 01 March 2018 Pages: 779 - 807

   

7. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

   • Guy Neff
   • Woodie Zachry III

   Systematic Review Open access 12 April 2018 Pages: 809 - 822

   

8. The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests

   • Alison F. Smith
   • Mike Messenger
   • Claire Hulme

   Systematic Review Open access 03 March 2018 Pages: 823 - 835

   

9. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England

   • Irina A. Tikhonova
   • Nicola Huxley
   • Martin Hoyle

   Original Research Article 01 March 2018 Pages: 837 - 851

   

10. Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist

    • Przemysław Holko
    • Paweł Kawalec
    • Andrzej Pilc

    Original Research Article Open access 17 April 2018 Pages: 853 - 865

    

11. Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK

    • Vanessa Buchanan
    • Will Sullivan
    • Bruce Kirkham

    Original Research Article Open access 25 May 2018 Pages: 867 - 878

    

12. Comment on: “A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis”

    • Ena Singh

    Letter to the Editor 04 May 2018 Pages: 879 - 879

13. Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

    • Guy Neff
    • Woodie Zachry III

    Correction Open access 01 June 2018 Pages: 881 - 881